Prognostic and predictive role of JWA and XRCC1 expressions in gastric cancer

Clinical Cancer Research

Volumn 18, Issue 10, 2012, Pages 2987-2996

  Wang, Shouyu ^a   Wu, Xuming ^a,b   Chen, Yansu ^a   Zhang, Jianbing ^a,b   Ding, Jingjing ^a   Zhou, Yan ^c   He, Song ^b   Tan, Yongfei ^c   Qiang, Fulin ^b   Bai, Jin ^a,d   Zeng, Jinyan ^a   Gong, Zhenghua ^a   Li, Aiping ^a   Li, Gang ^e   Røe, Oluf Dimitri ^f,g   Zhou, Jianwei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Nantong Cancer Hospital   (China)

^c Department of Oncology   (France)

^d XUZHOU MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^g Levanger Hospital   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; ONCOPROTEIN; OXALIPLATIN; PROTEIN JWA; TUMOR MARKER; UNCLASSIFIED DRUG; XRCC1 PROTEIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STOMACH CANCER;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHINA; COHORT STUDIES; DNA-BINDING PROTEINS; DOWN-REGULATION; FEMALE; FLUOROURACIL; HEAT-SHOCK PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUCOVORIN; MALE; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84861162589     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2863     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
2. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010;303:1729-37.
3. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-7. (Pubitemid 46631401) (Pubitemid 46631401)
4. Caldecott KW. Mammalian single-strand break repair: mechanisms and links with chromatin. DNA Repair (Amst) 2007;6:443-53.
5. de Boer J, Hoeijmakers JH. Nucleotide excision repair and human syndromes. Carcinogenesis 2000;21:453-60.
6. Helleday T, Lo J, van Gent DC, Engelward BP. DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst) 2007;6:923-35. (Pubitemid 46880473) (Pubitemid 46880473)
7. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 2004;44:239-67. (Pubitemid 38263841)
8. WilsonDM3rd, Bohr VA. The mechanics of base excision repair, and its relationship to aging and disease. DNA Repair (Amst) 2007;6:544-59.
9. CaldecottKW. Single-strand break repair and genetic disease. Nat Rev Genet 2008;9:619-31.
10. Kubota Y, Nash RA, Klungland A, Schar P, Barnes DE, Lindahl T. Reconstitution of DNA base excision-repair with purified human proteins: interaction between DNA polymerase beta and the XRCC1 protein. Embo J 1996;15:6662-70. (Pubitemid 26413798) (Pubitemid 26413798)
11. Taylor RM, Wickstead B, Cronin S, Caldecott KW. Role of a BRCT domain in the interaction of DNA ligase III-alpha with the DNA repair protein XRCC1. Curr Biol 1998;8:877-80. (Pubitemid 28356048) (Pubitemid 28356048)
12. El-Khamisy SF, Masutani M, Suzuki H, Caldecott KW. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res 2003;31:5526-33. (Pubitemid 37441922)
13. Li WQ, Zhang L, Ma JL, Zhang Y, Li JY, Pan KF, et al. Association between genetic polymorphisms of DNA base excision repair genes and evolution of precancerous gastric lesions in a Chinese population. Carcinogenesis 2009;30:500-5.
14. Goekkurt E, Al-Batran SE, Hartmann JT, Mogck U, Schuch G, Kramer M, et al. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol 2009;27:2863-73.
15. Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 2006;24: 3789-98. (Pubitemid 46628477) (Pubitemid 46628477)
16. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, Loader J, Terris B, Stamp G, et al. Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 2002;21:4587-94. (Pubitemid 34785735) (Pubitemid 34785735)
17. SakSC, Harnden P, Johnston CF, Paul AB, Kiltie AE. APE1 and XRCC1 protein expression levels predict cancer-specific survival following radical radiotherapy in bladder cancer. Clin Cancer Res 2005;11: 6205-11. (Pubitemid 41262949) (Pubitemid 41262949)
18. Wang S, Gong Z, Chen R, Liu Y, Li A, Li G, et al. JWA regulates XRCC1 and functions as a novel base excision repair protein in oxidativestress-induced DNA single-strand breaks. Nucleic Acids Res 2009; 37:1936-50.
19. Chen H, Bai J, Ye J, Liu Z, Chen R, Mao W, et al. JWA as a functional molecule to regulate cancer cells migration via MAPK cascades and Factin cytoskeleton. Cell Signal 2007;19:1315-27. (Pubitemid 46561567)
20. Bai J, Zhang J, Wu J, Shen L, Zeng J, Ding J, et al. JWA regulates melanoma metastasis by integrin alphaVbeta3 signaling. Oncogene 2010;29:1227-37.
21. Tang WY, Wang L, Li C, Hu ZB, Chen R, Zhu YJ, et al. Identification and functional characterization of JWA polymorphisms and their association with risk of gastric cancer and esophageal squamous cell carcinoma in a Chinese population. J Toxicol Environ Health A 2007;70:885-94. (Pubitemid 46699718) (Pubitemid 46699718)
22. Sakamoto H, Yoshimura K, Saeki N, Katai H, Shimoda T, Matsuno Y, et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet 2008;40:730-40. (Pubitemid 351748870) (Pubitemid 351748870)
23. Japanese Gastric Cancer A. Japanese classification of gastric carcinoma - 2nd English Edition. Gastric Cancer 1998;1:10-24.
24. Weichert W, Roske A, Gekeler V, Beckers T, Ebert MP, Pross M, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008;9:139-48.
25. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56: 337-44. (Pubitemid 30422619) (Pubitemid 30422619)
26. Tebbs RS, Thompson LH, Cleaver JE. Rescue of Xrcc1 knockout mouse embryo lethality by transgene-complementation. DNA Repair (Amst) 2003;2:1405-17. (Pubitemid 37464817) (Pubitemid 37464817)
27. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G.DNAsynthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356:800-8. (Pubitemid 46294612) (Pubitemid 46294612)
28. Gazdar AF. DNA repair and survival in lung cancer-the two faces of Janus. N Engl J Med 2007;356:771-3. (Pubitemid 46294609) (Pubitemid 46294609)
29. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatinbased adjuvant chemotherapy. N Engl J Med 2006;355:983-91. (Pubitemid 44343542)
30. Huang S, Shen Q, Mao WG, Li AP, Ye J, Liu QZ, et al. JWA, a novel signaling molecule, involved in the induction of differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun 2006;341: 440-50. (Pubitemid 43152124) (Pubitemid 43152124)
31. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33:9-23. (Pubitemid 46137553) (Pubitemid 46137553)
32. Yang J, Parsons J, Nicolay NH, Caporali S, Harrington CF, Singh R, et al. Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy. Oncogene 2010;29:463-8.
33. Zhang R, Niu Y, Zhou Y. Increase the cisplatin cytotoxicity and cisplatin-induced DNA damage in HepG2 cells by XRCC1 abrogation related mechanisms. Toxicol Lett 2010;192:108-14.
34. Moser J, Kool H, Giakzidis I, Caldecott K, Mullenders LH, Fousteri MI. Sealing of chromosomal DNA nicks during nucleotide excision repair requires XRCC1 and DNA ligase III alpha in a cell-cycle-specific manner. Mol Cell 2007;27:311-23. (Pubitemid 47058307)
35. Taylor RM, Moore DJ, Whitehouse J, Johnson P, Caldecott KW. A cell cycle-specific requirement for the XRCC1 BRCT II domain during mammalian DNA strand break repair. Mol Cell Biol 2000;20: 735-40. (Pubitemid 30023115) (Pubitemid 30023115)
36. Levy N, Martz A, Bresson A, Spenlehauer C, de Murcia G, Menissier-de Murcia J. XRCC1 is phosphorylated by DNA-dependent protein kinase in response to DNA damage. Nucleic Acids Res 2006;34:32-41. (Pubitemid 43160033) (Pubitemid 43160033)
37. Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol 2008;26:5630-7.
38. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26:1435-42.
39. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010;29:482-91.
40. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13:54-61. (Pubitemid 46067386) (Pubitemid 46067386)